MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
79.46
+0.09 (+0.11%)
At close: 4:00PM EDT

79.46 0.00 (0.00%)
After hours: 5:52PM EDT

Stock chart is not supported by your current browser
Previous Close79.37
Open79.02
Bid0.00 x 0
Ask0.00 x 0
Day's Range78.52 - 79.50
52 Week Range76.41 - 89.72
Volume3,935,098
Avg. Volume5,290,619
Market Cap107.698B
Beta0.73
PE Ratio (TTM)38.87
EPS (TTM)2.04
Earnings DateMay 24, 2018
Forward Dividend & Yield1.84 (2.34%)
Ex-Dividend DateN/A
1y Target Est91.44
Trade prices are not sourced from all markets
  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realist10 hours ago

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • Will BSX’s 1Q18 Results Support Its Upward Trend?
    Market Realist2 days ago

    Will BSX’s 1Q18 Results Support Its Upward Trend?

    Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist2 days ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings
    Market Realist2 days ago

    Boston Scientific: The Word on Wall Street ahead of 1Q18 Earnings

    The company has been growing aggressively through strategic acquisitions. This month, the company announced the acquisition of Nvision Medical Corporation in the area of women’s health and Securus Medical in the area of electrophysiology. The company is slated to announce its 1Q18 earnings results on April 25. In this article, let’s discuss the company’s Wall Street recommendations and target prices for the next 12 months.

  • Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions
    GlobeNewswire3 days ago

    Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

    April 23, 2018 - Medtronic plc (MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360mm in patients with peripheral artery disease (PAD). Approval was based on clinical data from the complex lesion imaging cohorts of the IN.PACT Global Study, including long lesion, in-stent restenosis, and chronic total occlusion (CTO) groups with lesion lengths 180mm.

  • GlobeNewswire3 days ago

    ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement

    WESTMINSTER, Colo., April 23, 2018-- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...

  • Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves
    Investor's Business Daily6 days ago

    Aortic Stenosis, And The Race To Catch Edwards Lifesciences' Heart Valves

    Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.

  • Benzinga8 days ago

    Medtech Supplier IntriCon Rallies After Bullish Stifel Initiation

    IntriCon Corporation (NASDAQ: IIN ), a medical technology company and major supplier to  Medtronic PLC (NYSE: MDT )'s diabetes division, is "one of the more interesting and undiscovered small-cap ...

  • Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres
    GlobeNewswire8 days ago

    Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres

    Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, ...

  • Morningstar10 days ago

    Medtronic's Portfolio Is Unmatched

    The wide-moat company leads the market in medical technology.

  • InvestorPlace12 days ago

    Tandem Diabetes Care Inc Is Up 194% — And It’s Not Done Yet

    When a stock jumps over 85% higher in a month and around 30 percent in just the last week, value investors would typically lose interest in the stock. Value investors would likely only consider buying TNDM stock on a pullback. Regardless of one’s investing style, the first step is looking into why Tandem Diabetes stock is soaring since February and then picking up steam in April.

  • Abbott’s Latest Valuation Metrics in April 2018
    Market Realist15 days ago

    Abbott’s Latest Valuation Metrics in April 2018

    On April 6, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings ratio) of 20.1x, while its PE was 57.6x. A lower forward estimate compared to the current PE represents analysts’ expectations that a company will generate higher earnings over the next 12 months.

  • Abbott Laboratories Goes Ex-Dividend on April 12, 2018
    Market Realist16 days ago

    Abbott Laboratories Goes Ex-Dividend on April 12, 2018

    The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.

  • Abbott’s Stock Price Momentum Continues: What’s Ahead?
    Market Realist16 days ago

    Abbott’s Stock Price Momentum Continues: What’s Ahead?

    On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.

  • Analysts’ Latest Recommendations and Target Prices for Abbott
    Market Realist16 days ago

    Analysts’ Latest Recommendations and Target Prices for Abbott

    Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.

  • Sleep-apnea device maker Inspire Medical files to raise $86.2M in IPO
    American City Business Journals16 days ago

    Sleep-apnea device maker Inspire Medical files to raise $86.2M in IPO

    The Maple Grove-based company, which spun out of Medtronic in 2007, plans to put the proceeds toward sales and marketing, product development and working capital.

  • Healthcare and biotech investor Sami Hamade dies
    American City Business Journals16 days ago

    Healthcare and biotech investor Sami Hamade dies

    Hamade had spent the past three-plus years as a partner with New York-based Apple Tree Partners.

  • GlobeNewswire16 days ago

    Medtronic to Unveil Additional Clinical Data on HVAD® System at ISHLT 2018

    Data on Implant Approach, Blood Pressure Management, Length of Stay, and Quality of Life to be Featured During Congress. DUBLIN - April 9, 2018 - Medtronic plc (NYSE: MDT) today announced a preview of ...

  • MitraClip Drives Growth, Gets Reimbursement Approval in Japan
    Market Realist16 days ago

    MitraClip Drives Growth, Gets Reimbursement Approval in Japan

    On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.

  • Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension
    GlobeNewswire17 days ago

    Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

    Pivotal Trial Now Underway to Study Effect of Investigational Procedure in Patients with High Blood Pressure DUBLIN - April 9, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration ...

  • What’s behind Edwards Lifesciences’ Latest Valuation
    Market Realist20 days ago

    What’s behind Edwards Lifesciences’ Latest Valuation

    Recent Developments at Edwards Lifesciences

  • Varian Medical Systems: Expanding in Proton Therapy
    Market Realist20 days ago

    Varian Medical Systems: Expanding in Proton Therapy

    Should Investors Be Interested in Varian Medical Systems?

  • Medtronic to Grow on Strong Fundamentals, High Costs a Woe
    Zacks20 days ago

    Medtronic to Grow on Strong Fundamentals, High Costs a Woe

    Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022

  • Edwards Lifesciences Gets CE Mark Approval for Its Centera Valve
    Market Realist21 days ago

    Edwards Lifesciences Gets CE Mark Approval for Its Centera Valve

    Recent Developments at Edwards Lifesciences